The 2023 ACR / EULAR Antiphospholipid Syndrome Classification Criteria
Arthritis & Rheumatology · 2023-10 · 75 (10) · 1687-1702
DOI: 10.1002/art.42624 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 28.08.2023. Verfasst von Medha Barbhaiya und 59 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, New York. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Rheumatology. Die Arbeit wurde bisher 507-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Objective
To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR.
Methods
This international multidisciplinary initiative included 4 phases: 1) Phase I, criteria generation by surveys and literature review; 2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; 3) Phase III, criteria definition, further reduction with the guidance of real‐world patient scenarios, and weighting via consensus‐based multicriteria decision analysis, and threshold identification; and 4) Phase IV, validation using independent adjudicators’ consensus as the gold standard.
Results
The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL‐associated clinical criterion, followed by additive weighted criteria (score range 1–7 points each) clustered into 6 clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and 2 laboratory domains (lupus anticoagulant functional coagulation assays, and solid‐phase enzyme‐linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti–β 2 ‐glycoprotein I antibodies). Patients accumulating at least 3 points each from the clinical and laboratory domains are classified as having APS. In the validation cohort, the new APS criteria versus the 2006 revised Sapporo classification criteria had a specificity of 99% versu s 86%, and a sensitivity of 84% versus 99%.
Conclusion
These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk‐stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, New York.
- Vascular Medicine Division, French National Referral Center for Systemic and Autoimmune Diseases, Université de Lorraine, Inserm, DCAC, and CHRU-Nancy, F-54000, Nancy, France.
- Department of Medicine and Obstetrics, Auckland City Hospital, Auckland, New Zealand.
- Department of General Medicine, Middlemore Hospital, Counties Manukau Health District, Auckland, New Zealand.
- CIC Clinical epidemiology, CHRU Nancy, Inserm, Université de Lorraine, Nancy, France.
- Department of Internal Medicine, Service of Rheumatology, ABC Medical Center, Mexico DF, Mexico.
ORCID-Profile: Medha Barbhaiya, Stephane Zuily, Laura Andreoli, Tadej Avcin, Guilherme de Jesus, Ali Duarte-Garcia, Michelle Petri, Guillermo Pons-Estel, Jose A Gomez-Puerta, Savino Sciascia, Maria G Tektonidou
Zitieren
APA
Barbhaiya, M., Zuily, S., Naden, R., Hendry, A., Manneville, F., Amigo, M. C., Amoura, Z., Andrade, D., Andreoli, L., Artim-Esen, B., Atsumi, T., Avcin, T., Belmont, H. M., Bertolaccini, M. L., Branch, D. W., Carvalheiras, G., Casini, A., Cervera, R., Cohen, H., …, & Willis, R. (2023). The 2023 ACR / EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis & Rheumatology, 75(10), 1687-1702. https://doi.org/10.1002/art.42624
Vancouver
Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, et al. The 2023 ACR / EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis & Rheumatology. 2023;75(10):1687-1702. doi:10.1002/art.42624
BibTeX
@article{Barbhaiya2023,
author = {Barbhaiya, Medha and Zuily, Stephane and Naden, Ray and Hendry, Alison and Manneville, Florian and Amigo, Mary-Carmen and Amoura, Zahir and Andrade, Danieli and Andreoli, Laura and Artim-Esen, Bahar and Atsumi, Tatsuya and Avcin, Tadej and Belmont, H Michael and Bertolaccini, Maria Laura and Branch, D Ware and Carvalheiras, Graziela and Casini, Alessandro and Cervera, Ricard and Cohen, Hannah and Costedoat-Chalumeau, Nathalie and Crowther, Mark and de Jesus, Guilherme and Delluc, Aurelien and Desai, Sheetal and De Sancho, Maria and Devreese, Katrien M and Diz-Kucukkaya, Reyhan and Duarte-Garcia, Ali and Frances, Camille and Garcia, David and Gris, Jean-Christophe and Jordan, Natasha and Leaf, Rebecca K and Kello, Nina and Knight, Jason S and Laskin, Carl and Lee, Alfred I and Legault, Kimberly and Levine, Steve R and Levy, Roger A and Limper, Maarten and Lockshin, Michael D and Mayer-Pickel, Karoline and Musial, Jack and Meroni, Pier Luigi and Orsolini, Giovanni and Ortel, Thomas L and Pengo, Vittorio and Petri, Michelle and Pons-Estel, Guillermo and Gomez-Puerta, Jose A and Raimboug, Quentin and Roubey, Robert and Sanna, Giovanni and Seshan, Surya V and Sciascia, Savino and Tektonidou, Maria G and Tincani, Angela and Wahl, Denis and Willis, Rohan},
title = {The 2023 ACR / EULAR Antiphospholipid Syndrome Classification Criteria},
journal = {Arthritis & Rheumatology},
year = {2023},
volume = {75},
number = {10},
pages = {1687--1702},
doi = {10.1002/art.42624}
}
EUVIMED